Effects of supplementary Da Dingfeng Zhu therapy on patients with Parkinson's disease of liver-kidney yin deficiency pattern.

BACKGROUND: This study aimed to verify whether the combined use of Da Dingfengzhu and Western medicine in treating Parkinson's disease (PD) can lead to therapeutic efficacy and symptom alleviation, thereby achieving a complementary and synergistic effect. METHODS: In this study, 158 patients were initially enrolled, with 116 eligible patients randomly divided into a control and an observation group. The control group received levodopa/benserazide and pramipexole, while the observation group received Da Dingfengzhu combined with levodopa/benserazide and pramipexole for 12 weeks. Baseline patient characteristics, adverse reactions, and blood samples were collected at baseline and 12 weeks post-treatment. The Unified Parkinson's Disease Rating Scale (UPDRS) was used to assess symptom severity at baseline, four weeks into treatment, and 12 weeks post-treatment. RESULTS: Adverse reactions during treatment were similar in both groups, suggesting that the combined therapy in the observation group did not increase adverse effects. Both groups showed improvements in UPDRS scores, with the observation group displaying more significant symptom alleviation at 4 and 12 weeks. Moreover, the observation group exhibited more pronounced increases in serum neurotrophic factor-3 and dopamine levels and greater reductions in oxidative stress and inflammatory response markers. CONCLUSION: In conclusion, the combination of Da Dingfengzhu with levodopa/benserazide and pramipexole for treating PD shows significant clinical potential and is worthy of broader application.

Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.

OBJECTIVES: We compared levodopa (LD) kinetic-dynamic profile of a dose of LD/aromatic amino acid decarboxylase peripheral inhibitors versus a nominally equivalent dose of a commercial Mucuna pruriens (Mucuna) seeds extract in 2 patients with Parkinson disease chronically taking LD standard combined with self-prescribed Mucuna. METHODS: Patients were challenged with a fasting morning dose of 100 mg LD/25 mg carbidopa (patient 1) or benserazide (patient 2) versus 100 mg LD from Mucuna capsules in 2 different sessions, after a 12-hour standard LD formulations' washout. They underwent kinetic-dynamic LD monitoring based on LD dose intake and simultaneous serial assessments of plasma drug concentrations and motor test performances. Quantitative analysis of LD in Mucuna capsules was also performed. RESULTS: Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna. In patient 1, impaired LD bioavailability from Mucuna resulted in reduced duration and overall extent of drug response compared with LD/carbidopa. In patient 2, no significant subacute LD motor response was observed in either condition. Quantitative analysis of Mucuna formulation confirmed the 100 mg LD content for the utilized capsules. CONCLUSIONS: Our results show an impaired LD bioavailability from Mucuna preparation, as expected by the lacking aromatic amino acid decarboxylase inhibitors coadministration, which might explain the suggested lower dyskinetic potential of Mucuna compared with standard LD formulations.

[Effects of "attenuation and synergia" for Bushenhuoxue Granules on Parkinson's patients].

OBJECTIVE: To study the effects of "Attenuation and Synergia" for Bushenhuoxue Granules (BSHXG) on Parkinson's patients. METHODS: 120 patients were enrolled and divided into two groups randomly, the control group were treated with placebo and treatment group with BSHXG, both groups based on Madopar treatment. Double-blinded clinical trial was adopted in treatment period. Follow-up period for 6 months. Usage of Madopar and score of treatment complications were adopted to measure related motor complications before and after treatment. RESULTS: Usage of Madopar and score of treatment complications in treatment group were decreased (P < 0.05). No adverse effects were found in this trial. CONCLUSION: BSHXG can decrease the side-effects of Madopar and put off the development of PD. The effects of "Attenuation and Synergia" of BSHXG becomes clear with time.

The metabolism of exogenous L-dopa in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain.

The characterization and localization of non-catecholaminergic cells producing dopamine after L-Dopa load have been investigated in the normal rat brain by a direct immunohistochemical labelling of amines using specific antibodies. The detection of dopamine-containing non-catecholaminergic cells has been achieved in rats given a commonly used mixture of L-Dopa plus peripheral decarboxylase inhibitor, and compared to controls. Results indicate that serotoninergic neurons tend toward a switch of their metabolism into dopamine production after L-Dopa load in a dose-dependent manner. In addition small non-aminergic cells, identified as aromatic amino-acid decarboxylase-containing cells, were observed to produce dopamine after exogenous L-Dopa load. Possible implications of such results concerning the mode of action of L-Dopa in the brain are discussed.